Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

Table 2 Characteristics of samples used in this study grouped by responses of cells to Tipifarnib and GO: CD34 ⁺ CD38 ^- cells

AML#	%CD34⁺CD38^-	CD123 MFI	CD33 MFI	Tip% cell loss¹	GO%cell loss¹	Tip/GO%cell loss¹	Δtox²
#13	3	92	—	88	96	100	-
#19	3.4	20	1.4	66	91	100	-
#1	40	51	193	61	40	96	-
#10	7.6	12	0.5	80	26	94	-
#33	0.3	46	143	26	67	94	1
#4	1.7	35	437	57	57	93	-
#14	45	319	9.7	59	25	93	9
#32	33	62	51	0	45	92	47
#11	2.5	35	61	12	53	91	26
#9	0.3	34	13	32	57	90	1
#34	2.6	70	1.5	44	31	86	11
#16	2.3	1.8	92	0	59	81	22
#17	7	4.9	16	21	51	81	9
#8	17	53	72	0	0	73	73
#15	78	23	3.4	47	16	72	9
#5	16	76	74	0	60	70	10
#6	0.2	19	57	0	66	66	0
#20	2.4	173	31	11	43	64	10
#3	9	8.4	12	15	0	63	48
#35	3.7	9.2	7.2	62	1	62	−1
#31	0.8	55	9.6	41	38	52	−27
#26	2.4	17	9	43	0	43	0
#25	12	42	3.2	15	2	38	21
#18	85	20	1.9	0	8	33	25
#29	0.9	62	31	0	64	27	−37
#27	14	20	100	0	0	26	26
#2	54	20	3.1	6	5	18	7
#36	53	6	6.2	27	9	14	−22
#7	23	11	15	0	5	0	−5
#12	0.3	29	7.5	0	34	0	−34
#21	6.2	24	53	0	0	0	0
#23	0.2	4.2	20	0	2	0	−2
#28	6	17	3.2	0	0	0	0
#30	2.4	90	34	0	0	0	0

34 AML samples used in this study ordered by magnitude of response to tipifarnib + GO (column second from the right).
¹% of cells lost after 48 hours treatment (compared to untreated control).
² Δtox = cell loss with drug combination – (cell loss with tipifarnib + cell loss with GO). No values are displayed when cell loss with tipifarnib + cell loss with GO= > 100%.

ISSN: 1471-2407